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Background: Identifying the predictors of noninvasive ventilation (NIV) failure has attracted significant interest
because of the strong link between failure and poor outcomes. However, very little attention has been paid to the
timing of the failure. This narrative review focuses on the causes of NIV failure and risk factors and potential
remedies for NIV failure, based on the timing factor.
Results: The possible causes of immediate failure (within minutes to <1 h) are a weak cough reflex, excessive
secretions, hypercapnic encephalopathy, intolerance, agitation, and patient-ventilator asynchrony. The major
potential interventions include chest physiotherapeutic techniques, early fiberoptic bronchoscopy, changing
ventilator settings, and judicious sedation. The risk factors for early failure (within 1 to 48 h) may differ for hypercapnic
and hypoxemic respiratory failure. However, most cases of early failure are due to poor arterial blood gas (ABGs) and an
inability to promptly correct them, increased severity of illness, and the persistence of a high respiratory rate. Despite a
satisfactory initial response, late failure (48 h after NIV) can occur and may be related to sleep disturbance.
Conclusions: Every clinician dealing with NIV should be aware of these risk factors and the predicted parameters of
NIV failure that may change during the application of NIV. Close monitoring is required to detect early and late signs of
deterioration, thereby preventing unavoidable delays in intubation.
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The utilization of noninvasive mechanical ventilation
(NIV) has become one of the most important develop-
ments in the field of mechanical ventilation over the past
two decades. The use of NIV during acute respiratory
failure (ARF) has increased since the late 1990s for all
diagnoses, including patients with and without chronic
obstructive pulmonary disease (COPD), regardless of the
supporting evidence for the later [1].
NIV failure has been defined as the need for endo-
tracheal intubation (ETI) or death [2]. Its rate greatly
varies between 5 and 60%, depending on numerous fac-
tors, including the cause of ARF [3,4]. Unsuccessful
NIV was found to be independently associated with
death, especially in patients with de novo ARF [5]. This* Correspondence: stefanava@gmail.com
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stated.may indicate the need for caution with regard to the ap-
plication of NIV and for close monitoring to switch
promptly to ETI when necessary.
Several investigators have tried to assess the best predic-
tors of NIV failure [6-12]. However, to the best of our
knowledge, despite the rather extensive literature in the
NIV field, there is only one paper, published 10 years ago,
summarizing the evidence for the risk factors for NIV fail-
ure, and no studies of the timing of the failure [13]. Based
on data from randomized controlled trials (RCTs), three
temporal moments were identified: 1) immediate failure
(within minutes to <1 h), 2) early failure (1 to 48 h), and
3) late failure (after 48 h) (Figure 1) [6-12]. The purpose of
this narrative review is to illustrate the main patient-
related predictors or risks factors of immediate, early, and
late failure. We also discuss possible remedies to avoid
ETI and nonpatient-related risk factors.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Figure 1 Mean NIV failure rates based on timing according to
the data of randomised controlled trials (6–12).
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Immediate NIV failure
Immediate NIV failure refers to failure within minutes
and not beyond the first hour. Excluding patients with
contraindications for NIV use (Table 1) [4], about 15% ofTable 1 Indications and contraindications for NIV in acute
care [4,16,17,35]
Indications:
A- Gas exchange:
• Acute or acute on chronic ventilator failure (best indication),
PaCO2 > 45 mmHg
• Ph < 7.35
• Hypoxemia (use with caution), PaO2/FIO2 ratio < 200
B- Bedside observations:
• Increased dyspnea- moderate to severe
• Tachypnoea (24 breaths per minute in obstructive, >30 per minute
in restrictive)
• Signs of increased work of breathing, accessory muscle use, and
abdominal paradox
Absolute contraindications:
• Cardiac or respiratory arrest
• Unable to fit mask
Relative contraindications:
• Non-respiratory organ failure (severe encephalopathy with GCS < 10,
severe upper gastrointestinal bleeding, hemodynamic instability or
unstable cardiac arrthythmia)
• Inability to cooperate/protect the airway
• Inability to clear respiratory secretions
• High risk of aspiration
• Recent facial surgery, trauma, or deformity
• Upper airway obstruction
NIV: Noninvasive ventilation, GCS: Glasgow coma scale.all NIV failures were defined as “immediate” in RCTs, ir-
respective of the underlying causes of ARF [6,10,11].
Predictors of failure in this period have never been sys-
tematically analyzed. The causes of NIV failure and pos-
sible remedies are reviewed below (Table 2).
Weak cough reflex and/or excessive secretions NIV
does not allow direct access to the airways. A weak
cough reflex leading to inefficient clearance of excessive
secretions from airways is a common cause of immedi-
ate NIV failure [14,15]. The inability to spontaneously
remove secretions is considered a relative contraindi-
cation for NIV, especially in patients with impaired
consciousness and depressed cough [16,17]. Some data
indicate that specific “manual” or “mechanical” physio-
therapeutic techniques may improve mucociliary clear-
ance during NIV and that NIV can still be used in
those circumstances [18,19]. Intrapulmonary percus-
sive ventilation (IPV) is a technique that delivers small
bursts of high-flow respiratory gas at high rates for
mobilization of secretions [20]. Two clinical studies dem-
onstrated that IPV used before or in combination with
NIV may reduce the risk of ETI in COPD patients with
difficulties removing secretions [19,21]. Early fiberoptic
bronchoscopy is another potential intervention that can
be used to minimize the burden of respiratory secretions.
In a matched case–control study, early suction of secre-
tions performed during NIV was shown to be feasible and
safe [22]. However, in a recent prospective multicenter
study, ventilatory support needed to be increased after
fiberoptic bronchocopy in 35% of patients with hypoxemic
respiratory failure [23].
In conclusion, for patients with a weak cough reflex or
excessive secretions, cautious secretion management
during NIV use might be advisable before NIV is de-
clared as failed [4,24].
Hypercapnic encephalopathy and coma Hypercapnic
encephalopathy (HES) is often considered a cause of im-
mediate NIV failure because of poor compliance due to
confusion and/or agitation. Additionally, it is viewed as a
relative contraindication because of the increased risk of
aspiration [16].
A number of studies clearly demonstrated that cau-
tious application of NIV can be attempted in patients
with HES by an experienced team to achieve a fast re-
duction of PaCO2 and to re-institute the conditions for a
successful NIV attempt [25,26]. The risk of aspiration
has been shown to be minimized by the rapid improve-
ment of neurological status under NIV and NIV failure
rates were reported to be comparable among patients
with and without HES [25]. The use of a relatively high
back-up rate and/or pressure control ventilation may
also help to “capture” the patient better [26]. Another
Table 2 The risk factors and suggestions for the management of NIV failure based on timing
Time Risk factors Suggested interventions References
Immediate 1. Weak cough reflex and/or excessive secretions 1a. Manual or mechanic chest physiotherapeutic techniques; b. Early
fiberoptic bronchoscopy.
[14-24]
2. Hypercapnic encephalopathy and coma 2a. Set a back-up rate ~ 15 b/min and/or use PCV; b. Decrease the FİO2
level.
[16,25-27]
3. Intolerance and psychomotor agitation 3. Judicious sedation [14,28-32]
4. “Fighting with the machine”: Patient-ventilator asynchrony 4a. Closely monitor ventilator waveforms; b. Judicious sedation;
c. Use a ventilator with an NIV platform; d. Change ventilatory parameters;
e. Minimize air-leaks.
[33,34]
Early
Hypoxemic
ARF
1. Baseline ABG and inability to correct gas exchange (P/F < 150)* [4] ([36,38,39,42*])
2. Baseline severity scores (SAPS II >35)* [1,5,36*,37*,39,43,49*-51]
3. The presence of ARDS/pneumonia/sepsis/multiorgan failure (OR: 4-28)* [36*,40,41,49,50,52*-54]
4. Increased respiratory rate (>25 breaths/min)* [51*,53,55*,56]
5. Miscellaneous: Delay between admission and NIV use, Number of fiberoptic
bronchoscopes performed, Duration of NIV use, Increase in radiographic
infiltrates within the first 24 hours, Causal diagnosis (as ‘de novo’)
[1,36,43,51,53,57]
Hypercapnic
ARF
1. Baseline ABG and inability to correct gas exchange (pH < 7.25)* [3*,6,12,14,58-60,62,63]
2. Increased severity of disease [3,12,14,15,59,62,64]
3. Increased respiratory rate (>35 breaths/min, OR for baseline and after 2 hours
of NIV: 2.66 and 4.95)*
[3*,6,15,58,59]
4. Mixed indices:
GCS, APACHE II score, respiratory rate and pH [3]
Respiratory rate, random glucose level and APACHE II [66]
Anemia and World Health Organization Performance Status (WHO-PS) [67]
5. Miscellaneous: Poor nutritional status, Increased heart rate, Higher baseline C-
reactive protein/white blood cell count, Lower serum potassium, Airway
colonization by non-fermenting gram-negative bacilli
[63,68,69]
Late 1. Sleep disturbance 1a. Improve quality of sleep; b. Avoid excessive noise and light
in the unit
[70]
2. Functional limitation [2]
3. Possible initial improvement in pH 3a. Close and continuous monitoring of vital parameters; b. Repeat
frequent ABGs during NIV, even when gas exchange reach a satisfactory
value
[2,64]
4. Hyperglycemia 4. Check glucose levels [2]
Odd Ratio (OR) or absolute “predictive” values for some parameters are reported from the studies quoted in the references and marked with * from other references.
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high-fractionated oxygen (FİO2) on the PaCO2 and pH,
known as the “Haldane effect” [27]. This effect can be
prevented by a simple intervention: decreasing the FİO2
level.
Intolerance and psychomotor agitation Patient toler-
ance has been shown to be critical for NIV success, es-
pecially in the first few minutes while the patient adapts
to this “new mode” of breathing [14]. Interfaces can lead
to intolerance. However, the role of these interfaces will
be discussed later because they are not directly related
to the patient.
The use of judicious sedation may be valuable to
achieve a sedation level that keeps the patient awake,
easily arousable, and comfortable. Ideal sedatives should
be short acting and have no significant effects on re-
spiratory drive and hemodynamics [28-30]. Remifentanil,
an opioid with an elimination half-life less than 10 min,
provides rapid onset of sedation and easy arousal. Two
pilot studies performed in patients who initially failed an
NIV trial due to intolerance and therefore met ETI cri-
teria showed that the administration of remifentanil re-
moved the need for intubation in most of the patients
[31,32]. A pilot study showed that a safe and satisfactory
level of sedation during NIV could be achieved with dexme-
detomidine, an alpha-2-adrenoceptor agonist [30]. Com-
pared to midazolam, dexmedetomidine led to a more
desired level of awaking sedation, and it shortened the
duration of mechanical ventilation and ICU stays in pa-
tients with acute cardiogenic pulmonary edema.
Although sedation has been suggested as a remedy
for intolerance, the “real life experience” shows that,
only a minority of physicians use sedation and analgesia
during NIV as a routine and it is usually without a spe-
cific protocol [29].
It has to be kept in mind that oversedation during NIV
can be potentially dangerous. Thus, close monitoring with
evaluation of arterial blood gas (ABG), cardiopulmonary
and ventilator parameters, adverse events, and the level of
sedation is mandatory.
Fighting with the machine: patient-ventilator asyn-
chrony Asynchrony has rarely been cited as a direct
cause of NIV immediate failure. However, indirect evi-
dence suggests that this may be the case [33]. Asynchrony
can easily be detected by a physical examination (e.g.,
number of spontaneous breaths vs. ventilator-delivered
breaths, accessory muscle use) of the patient and symp-
toms (e.g., dyspnea). Two main causes of asynchrony are a
high level of ventilator support and an increased number
of leaks.
A number of strategies can be implemented to avoid
“gross asynchronies,” such as optimization of ventilatorsettings using the screen ventilator waveforms, adjusting
trigger sensitivity, increasing positive end-expiratory
pressure, minimizing leaks, using different modes or
more sophisticated ventilators [33]. New modes of ven-
tilation, such as neutrally adjusted ventilator assist, have
been documented to reduce asynchrony [34].
Early NIV failure
Nearly 65% of NIV failures occur within 1–48 h of NIV
use (Figure 1), [6-8,10,12]. This time interval has re-
ceived more attention in assessments of predictors of
failure. As most studies have focused on NIV use in ei-
ther hypercapnic or pure hypoxic ARF, these two condi-
tions will be considered separately. Rather than giving
possible solutions, as in the previous section (Section 1),
we will discuss the most reasonable clinical decision to
be applied.
Hypoxemic respiratory failure Hypoxemic ARF can be
the end point of several pathologies, including pneumo-
nia, acute respiratory distress syndrome (ARDS), and
cardiogenic pulmonary edema (CPE), each of which acts
through different mechanisms (e.g., shunting, ventila-
tion/perfusion mismatch, or diffusion limitation). Robust
RCTs of the utilization of NIV for hypoxemic ARF are
scarce, explaining the absence of specific recommenda-
tions in evidence-based guidelines [35]. Therefore, it is
difficult to make general statements about risk factors
and predictive factors of NIV failure covering all causes
of hypoxemic ARF (Table 2).
Baseline ABG and inability to correct gas exchange
Oxygenation impairment, as shown by a decreased ratio
of PaO2 to FiO2 (P/F ratio), is one of the most well-
documented risk factors and predictors of NIV failure. The
outcomes of the patients are probably more dependent on
the underlying cause, rather than on the baseline severity of
the hypoxemia itself. A prospective multicenter study inves-
tigating variables predictive of NIV failure in 354 patients
with hypoxemic ARF reported a higher ETI rate in patients
with ARDS (51%) and community-acquired pneumonia
(CAP) (50%) than in patients with pulmonary contusion
(18%) and CPE (10%) [36]. In this study, most ETIs oc-
curred due to the inability of NIV to correct gas ex-
change (62%). Although the ABG values at study entry
had no predictive value, severe hypoxemia (P/F ≤146)
after 1 h of NIV treatment was reported to be an inde-
pendent predictor of NIV failure according to multivari-
ate analysis [36].
ARDS and CAP
In a group of patients with ARDS, the inability to im-
prove the P/F ratio after 1 h of NIV use (P/F ≤175) was
shown to be an independent predictor of NIV failure [37].
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the baseline P/F ratio (<120) was shown to be the only
factor associated with NIV failure [38]. Likewise, a low
P/F ratio at admission was found to be a risk factor
for immune-suppressed patients with pneumonia and
extrapulmonary sepsis and for patients with H1N1
pneumonia [39,40] and acute lung injury (ALI) (in this
latter group with an odd ratio = 1.03, per unit decrease
in PaO2/FiO2) for NIV failure [41]. P/F ratios at both
baseline (around 115) and after 1 h of NIV use (around
140) were indicated as independent predictors of NIV fail-
ure in patients with severe CAP [42].
Metabolic values on ABGs, other than oxygen levels,
should also be carefully assessed. The serum bicarbon-
ate level, as well as the P/F ratio, 1 h after NIV onset
was an independent predictor of NIV failure in patients
with CAP and severe ARDS [43]. Metabolic acidosis
was reported to be a significant predictor of unsuccess-
ful NIV in patients with ALI [41].
Cardiogenic pulmonary edema (CPE)
Generally, the rate of NIV failure is very low in pa-
tients with CPE. In a study of 2430 patients, the NIV
success rate was 96%, and oxygen saturation was
lower in the failure group [44]. Masip et al. demo-
nstrated that acute myocardial infarction, a low pH
(<7.25), a low ejection fraction (<30%), hypercapnia,
and low systolic blood pressure (<140 mmHg) were
independent predictors for ETI [45]. A pH level of
7.03 was shown to be a cut-off level to predict NIV
success, with the highest sensitivity and specificity
observed in patients with CPE [46].
To summarize, the severity of hypoxemia and acid-
osis and their initial responses to NIV are strong pre-
dictors of NIV outcomes. NIV should be performed
very cautiously, especially in patients with a P/F < 150
and diagnosed as ARDS or CAP. Vital signs and ABGs
should be monitored very closely, starting even before
the “classical” 60 min frame. The initial amelioration
of ABGs does not imply that NIV will be successful,
and strict monitoring should be continued in the fol-
lowing days [36-41].
Baseline severity scores
Although some previous research failed to indicate any
relationship between baseline severity scores (reflecting
the severity of the disease) and NIV outcomes [47,48],
most recent trials clearly confirmed this relationship
[1,5,36,37,49].
Higher SOFA, APACHE II, and/or SAPS II scores
were related with NIV failure in studies performed in
either all patients with ARF or patients with hypoxemic
ARF postoperatively or hypoxemic ARF due to sepsis, pneu-
monia or hematological malignancies [1,5,39,43,49-51]. AnSAPS II score ≥34 was identified as an independent risk fac-
tor for NIV failure in hypoxemic ARF [36,37].
To avoid harmful delays in ETI, these indexes should
always be evaluated in patients using NIV with these dis-
orders. It should be kept in mind that an SAPS II score
in the middle 30s is associated with a very high risk of
failure.
Presence of ARDS/pneumonia/sepsis/multiorgan failure
As stated earlier (2.1.1), underlying disease is the
major risk factor for NIV failure. De novo ARF was
shown to be associated with NIV failure and subse-
quent ETI in all ARF patients administered NIV [1,5].
In an observational study, the presence of ARDS or
CAP was identified as a risk factor for NIV failure
(OR = 3.75) [36]. In an RCT, ARDS was significantly
associated with ETI (OR = 28.5) [52]. These findings
were also confirmed in patients with pulmonary infil-
trates due to hematological malignancy or CAP in
postoperative ARF [49,50,53].
Multiorgan failure and hemodynamic instability have
been documented as risk factors of NIV failure in im-
munosuppressed patients with hypoxemic ARF [40,53].
In an observational study, 35% of patients with ALI re-
quiring NIV were diagnosed with septic shock, and NIV
failed in all the patients [41].
At present, we cannot recommend the use of NIV in
patients with moderate to severe hypoxia (P/F = <200)
diagnosed with ARDS or CAP or in patients with septic
shock, in agreement with the statement of the surviving
sepsis campaign [54].
Increased respiratory rate
An increased respiratory rate 1 h after NIV is a fre-
quently reported risk factor for NIV failure in patients
with ARF postoperatively or ARF due to hematological
malignancies or ALI [51,53,55]. These studies sugges-
ted that an average respiratory rate >25 breaths/min on
NIV is a predictor of failure because it is a surrogate of
increased work of breathing. The so-called rapid shal-
low breathing index >105 (i.e., the ratio between the
breathing frequency/tidal volume) under NIV has also
been demonstrated to be independently associated with
ETI (multivariate OR: 3.70) [56].
Miscellaneous risk factors of NIV failure
Other risk factors for NIV failure in hypoxemic ARF
are the delay between admission and NIV use, num-
ber of fiberoptic bronchoscopies performed, duration
of NIV use, increase in radiographic infiltrates within
the first 24 h, and causal diagnosis (as de novo) of
ARF [1,43,51,53]. Age has been demonstrated to be
a risk factor (with a low OR) only in a minority of
studies [1,36,57].
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The utilization of NIV in hypercapnic ARF, as well as
the risk factors for its failure, has probably been more
intensively studied compared to its use in hypoxic ARF
(Table 2). Although hypercapnic ARF covers ARF due
to neurological disorders (such as neuromuscular dis-
orders) or other acute or chronic lung disorders (such
as restrictive lung disease), most of the studies done in
this field have involved patients with COPD exacerba-
tions [3,58].
Baseline ABG and inability to correct gas exchange
The pH level, which is an indicator of the severity of hy-
percapnia, has been reported to be a critical factor in de-
termining the success of NIV. Although some reports
failed to show any relationship between baseline ABGs
and the success of NIV [15,48], a large body of evidence
clearly indicated that a lower baseline pH is a risk factor
for NIV failure in COPD patients [3,6,12,14,58-60]. In
nearly 50–60% of patients with a baseline pH of <7.25,
NIV was unsuccessful [6,12]. A subgroup analysis of
COPD patients with mild to moderate acidosis revealed
that NIV improved patient outcomes only if the baseline
pH was ≥7.30 [58].
In addition to baseline levels, pH values 1 h after the
application of NIV were shown to be strong predictors
of the success of NIV, with high sensitivity and good
specificity (93% and 82%, respectively) [59]. In a study of
more than 1000 COPD patients, Confalonieri et al.
pointed out that a pH <7.25 after 1 h of NIV use was as-
sociated with an increased risk of failure and that the
risk of failure was even greater than when the pH levels
were <7.25 at admission [3].
For the above mentioned reasons, we do not recom-
mend routine use of NIV in patients with a pH <7.25
outside a “protected” environment [16,17]. However, re-
cently, NIV has been offered as an effective treatment
option for patients with severe acidosis due to COPD,
even if performed in a respiratory ward [61]. In this
study, NIV improved pH and PaCO2 to the same extent
in two groups of patients with mild acidosis and severe
acidosis (pH <7.25) and overall survival rate was also
comparable. However, the study’s findings should be
interpreted cautiously. RCTs are required to confirm
that NIV can be safely applied in patients with severe
acidosis outside step-down units or ICUs.
Risk factors and predictors of NIV failure were also
assessed in non-COPD patients with hypercapnic ARF.
A low P/F ratio (on average <200), higher PaCO2, and a
lower pH after 1 h of NIV were reported as independent
predictors of NIV failure in a subset of heterogeneous
patients, including those with bronchiectasis and pul-
monary tuberculosis sequelae [62,63].Increased severity of disease
The relationship between NIV failure and the severity
scores, including APACHE II and SAPS II, has been
documented in a number of reports. Several researchers
found an association [3,12,14,15,59,62,64], whereas others
failed to find any association [5,48]. Interestingly, in a
study of more than 500 patients, although a high SAPS II
was a strong indicator of NIV failure and death in hypoxic
ARF, this was not the case for hypercapnic ARF (OR =
3.05 vs. 1.17, respectively) [5]. Therefore, in this latter
population, the presence of acute or chronic comorbidities
may be stronger risk factors for NIV failure than the sever-
ity indices [65].
Increased respiratory rate
An initial high respiratory rate and its reduction after
1 h of NIV have been shown to be associated with suc-
cessful NIV outcomes in COPD patients [6,15,58,59]. A
respiratory rate of 30–34 and ≥35 breaths/min at admis-
sion were demonstrated to lead to NIV failure, with an
OR of 1.83 and 2.66, respectively, whereas the ratios in-
creased to 2.67 and 4.95, respectively, for the same
breathing frequency after 2 h of NIV [3].
Mixed indices
Some investigators have suggested using mixed indices
to improve the probability of the prediction of NIV
failure. A risk stratification chart of NIV failure dem-
onstrated that COPD patients with a Glasgow Coma
Scale (GCS) <11, an APACHE II score ≥ 29, a respira-
tory rate ≥30 breaths/min, and a pH <7.25 at admis-
sion had a risk of failure >70% [3]. The risk increased
up to 95% for the same parameters after 2 h of NIV
therapy [3]. The prediction of NIV success was 97%
with a combination of a respiratory rate <30 bpm and
glucose <7 mmol/L [66]. Anemia and a World Health
Organization performance status (WHO-Performance
Status) score ≥3 were also shown to be significant pre-
dictors of mortality and NIV failure [67].
Thus far, the risk chart developed by Confalonieri
et al. [3] is probably the best mixed index for predicting
NIV outcomes with reasonable accuracy.
Miscellaneous
Poor nutritional status (i.e., a low BMI), a high white blood
cell count, low serum potassium, and an increased heart
rate are additional risk factors for NIV failure [63,68]. Two
additional issues may merit specific consideration. Old age
has never been shown to be a “negative” variable in deter-
mining NIV outcomes, and older patients with hypercapnic
ARF may respond even better than younger ones to NIV
[69]. The combination of ARF and pneumonia is probably
one of the strongest determinants of NIV failure [59],
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the RCTs excluded a priori these patients.
Late NIV failure
Although the definition of late NIV failure has not been
standardized; it is usually defined as failure that occurs
48 h after initiation of NIV, following an initial success-
ful response. Late NIV failure has received less attention
and has been studied mainly in hypercapnic ARF.
[2,6-8,10,12,64,70]. Actually, it occurs in a considerable
subset of patients (about 15% of NIV failures) (Figure 1).
The occurrence of late failure in COPD patients admit-
ted with hypercapnic ARF to ICUs when NIV was used
>24 h was found to be associated with functional limita-
tion before admission, the presence of hyperglycemia, and
a lower pH at admission [2]. PaCO2 and pH values im-
proved gradually and similarly within the first 24 h in both
success and late failure groups [2]. This is of particular im-
portance because initial good responses to NIV may de-
crease attention and monitoring by clinicians in the
following hours [2,64]. During a hospital stay, pneumonia
was more frequently observed as a complication in a late
failure group compared to a success group (12.9% vs. 0%)
[2]. It is logical that the occurrence of infectious complica-
tions and/or multiple organ failure may result in late NIV
failure, but such risk factors have never been addressed in
a trial. The mortality of a late failure group was extremely
high compared to a successful group in another study (68
vs. 0%) [2]. In a recent study, sleep disturbance (classified
as an abnormal electroencephalographic pattern, greater
circadian sleep-cycle disruption, and less nocturnal rapid
eye movement sleep) and increased delirium during an
ICU stay were also associated with late NIV failure in hy-
percapnic patients [70].
NIV patients should be continuously monitored (in-
cluding their sleep patterns and state of delirium), even
if their initial clinical and ABG responses are good be-
cause late NIV failure can lead to high mortality.
Non-patient related risk factors
The timing of the application of NIV is a critical factor.
A longer delay between admission and NIV use was
shown to be an independent risk factor for NIV failure
in patients with hematological malignancy and hypox-
emic ARF, probably due to the progression of the
underlying disease [53]. Therefore, early use of NIV is
recommended. It is also critical not to unduly delay
the decision to intubate a patient with failed NIV, be-
cause the risk of unanticipated respiratory or cardiac
arrest could lead to increased morbidity and mortality.
The location of the NIV therapy is another important
determinant in the success of NIV. There are advan-
tages and disadvantages of different locations (including
ICUs, step-down units, wards, and emergency care) forNIV application, and these have been discussed in detail
elsewhere [71]. The decision about where to perform
NIV should be based on matching the capabilities of the
units and teams with the patient’s clinical severity and
the need for monitoring.
The experience and the skills of the staff are other key
components of NIV success. One study suggested that
training in NIV implementation is an important factor
in reducing nasocomial infections and improving sur-
vival in critically ill patients with COPD and ACPE [72].
Another found that improvements in skill with time
may explain the decreased time spent by nurses at the
bedside of patients today compared to data reported
20 years ago [73].
The choice of ventilator is crucial in NIV success in
the acute setting, with inadequate equipment leading to
poor tolerance and excessive air leaks being documented
as a barrier to NIV use [74]. On average, dedicated NIV
platforms perform better than ICU ventilators using the
NIV algorithm [75]. In particular, the synchrony between
the machine and the patient is better with dedicated
NIV platforms [75].
Although much attention has been paid to the devel-
opment of new interfaces to increase tolerance and pa-
tient comfort, mask intolerance remains a major cause
of NIV failure [32]. An oronasal mask is generally the
most commonly preferred one in ARF, followed by nasal
masks, helmets, and mouthpieces. There are various ad-
vantages and disadvantages of these interfaces. In the
case of poor tolerance, a wise choice may be the appli-
cation of the so-called “rotating” strategy proposed by
Hilbert et al. [76].
Some authors concluded that humidification during
NIV for ARF is controversial and that the effect of hu-
midification on the success of NIV is unclear [77]. How-
ever, heated humidification is recommended to minimize
the work of breathing and to maximize PaCO2 clearance,
with less dead space than ventilators with heat and mois-
ture exchangers.
Conclusions
Risk factors and predictors of NIV failure are numerous.
They differ between hypercapnic and hypoxemic pa-
tients and according to the timing of the failure. Every
physician dealing with NIV should be aware of these risk
factors and closely monitor each patient for their pres-
ence or development to achieve a good response and to
improve the prognosis. If a patient fails to improve suffi-
ciently, prompt ETI should be performed without a
delay because there is an increased risk of morbidity and
mortality with ETI after failed NIV. A satisfactory initial
NIV attempt is not always a marker of a good outcome.
Late NIV failure may occur in up to 15% of patients in
whom the initial NIV attempt was satisfactory.
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